Incept, LLC

Ocular Therapeutix, Inc.

Genzyme Corporation

Other

Sherwood Services Ag

Peter K Jarrett

Charles D Blizzard

Rami El-Hayek

Amarpreet S Sawhney

Michael Goldstein

Timothy S Jarrett

Arthur Driscoll

Andrew Vanslette

Michael J McGrath

Michael Bassett

Andrew C Vanslette

Courtney A Rosales

Joseph Iacona

Erica Kahn

Luis Z Avila

Zachary Lattrell

Arthur J Coury

Stephen D Goodrich

Ronald S Rudowsky

Michelle D Lyman

Ankita D Desai

Hildegard M Kramer

Erik Wong

Chandrashekhar Prabhakar Pathak

Stephen Jack Herman

Shikha P Barman

Laurence A Roth

C Michael Philbrook

James F Biggins

Douglas J Weaver

Fei Yao

William C Nason

Michelle D Powell

Jeffrey A Hubbell

David J Enscore

Eric Dickinson

Sarah Guedez

Rami El-hayek

Rabia Gurses-ozden

Mark Ransbottom

Olivia Sherman

Rami El Hayek

Elizabeth Braun

Chintan Patel

John F Traverse

William Isom

Louis Rosati

Michael J Mcgrath

Kevin M Berrigan

Patrick K Campbell

George Jessup

Chris Martin

John W Maney

Ankita Darshan Desai

The invention relates to a sustained release biodegradable ocular implant containing axitinib dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

Ocular implant containing a tyrosine kinase inhibitor

The invention relates to a sustained release biodegradable ocular implant containing a tyrosine kinase inhibitor dispersed in a hydrogel for the treatment of a retinal disease for an extended period of time.

A system () includes a first assembly (A) and a second assembly (B). The first assembly (A) includes a body () forming a first interior volume, a plunger () comprising a first distal end disposed within the first interior volume, a wire comprising a first distal end secured to the first distal end of the plunger (), and a plunger clip () configured to interface with the plunger () and the body () to prevent actuation of the plunger (). The second assembly (B) includes a cowl () forming a second interior volume, a needle comprising a hub and a shaft, and a cowl cap disposed partially within the hub to secure the implant in the shaft. A first distal end of the shaft is connected to the hub. The hub is disposed within the second interior volume. The shaft is configured to receive an implant.

Implant injector device

Methods of treating an eye for an ocular condition such as placing a composite depot comprising a xerogel with embedded degradable particles into an anterior chamber of an eye to deliver a therapeutic agent. The xerogel is a hydrogel after exposure to intraocular fluid and is degradable. The degradable particles comprise the therapeutic agent and hydrolytically degrade in the anterior chamber to provide a controlled release of the therapeutic agent into the eye. Materials and processes for making depots are provided as well as alternative methods of their use.

Intracameral drug delivery depots

Provided herein are sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent

Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine

Disclosed in certain embodiments is an intracanalicular injectable applicator device includes a body forming a cavity and a cannula coupled to a first distal end of the body. The cannula forms a channel that is aligned with the cavity of the body. The cannula is configured to store an intracanalicular injectable in the channel. The intracanalicular injectable applicator device further includes a tip structure coupled to the body. The tip structure is disposed around at least a portion of the cannula. A distal end of the tip structure is configured to dilate a lacrimal punctum by inserting the distal end of the tip structure into the canaliculus via the lacrimal punctum. The intracanalicular injectable applicator device further includes an actuating structure configured to push the intracanalicular injectable through the channel and the distal end of the tip structure into a canaliculus via a lacrimal punctum.

Intracanalicular depot inserter device

Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.

Shape changing drug delivery devices and methods

Serial-solvent biomaterials are described. Embodiments include materials made in an organic solvent that are stripped of the solvent and used in a patient, where they imbibe water and form a hydrogel. These materials are useful for, among other things, delivering therapeutic agents, tissue augmentation, and radiological marking.

Medical organogel processes and compositions

This invention relates to methods of treatment with a sustained release biodegradable ocular implant containing a tyrosine inhibitor dispersed in a hydrogel.

Methods of treatment with an ocular implant containing a tyrosine kinase inhibitor

Drug delivery involving hydrogels as used for various medical conditions, and includes hydrogels formed in an eye with extended drug release times. An embodiment of the invention is a method of delivering a therapeutic agent to a tissue comprising forming a hydrogel in situ in an eye with a therapeutic agent dispersed in the hydrogel, the agent having a low solubility in water. The agent may be essentially insoluble in water. The hydrogel may be made so that 50% to 100% w/w of the agent is released when the hydrogel is from 100% to 50% persistent, with the persistence being a measure of the dry weight of the hydrogel relative to an initial dry weight of the hydrogel.

Drug delivery from hydrogels

Growing community of inventors

Sudbury, MA, United States of America

Peter K Jarrett